GBP2 and nonpapillary renal cell carcinoma: Zhao et al. [31] based on the TCGA database report increased expression of GBP1 in kidney renal clear cell carcinoma cases, and by examining 33 cancer types, they suggested that generally, patients with high GBP1 expression may possibly result in better responses to immunotherapy; however, other studies like the one by Ye et al. [32] show that GBP2, which is highly co-expressed with GBP1, is a robust prognostic biomarker for high immune infiltration and poor prognosis in ccRCC.